Effectiveness of antidementia drugs in delaying Alzheimer's disease progression  Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody  Alzheimer's & Dementia: The Journal of the Alzheimer's Association  Volume 9, Issue 3, Pages 338-345 (May 2013) DOI: 10.1016/j.jalz.2012.01.002 Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 1 Predicted long-term trajectories and effect size estimates: Atri et al study. Mean (A) BDS values and (B) ADL values predicted by longitudinal model for patients in the different medication regimens: combination therapy, ChEI monotherapy, and no therapy. Cohen-defined effect sizes for ADL and BDS values: ChEI monotherapy versus combination therapy, combination therapy versus no therapy, and combination therapy versus ChEI monotherapy. Abbreviations: ADL, Weintraub Activities of Daily Living Scale; BDS, Information-Memory-Concentration subscale of the Blessed Dementia Scale; ChEI, cholinesterase inhibitor; COMBO, combination therapy (ChEI plus memantine); NO-RX, no treatment. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 2 Time to nursing home placement: Lopez et al study. Survival analysis or time to nursing home admission in cohort 1 using the untreated patients as the reference group (A), and time to nursing home admission in cohort 2, using ChEI monotherapy as the reference group (B). Reproduced with permission from Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, DeKosky ST. J Neurol Neurosurg Psychiatry, 2009;80:600–7BMJ Publishing Group Ltd. Abbreviation: ChEI, cholinesterase inhibitor. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions

Fig. 3 Decline rates on neuropsychological tests by persistency group: Rountree et al study. Annualized rates of decline on (A) (E) cognitive, (B) (F) global, and (C) (D) functional measures. The graphs in Figure 3 present the trend of each predicted neuropsychological test value from the adjusted model by the whole drug persistency index group. Each predicted value was regressed on the time since entering the study, taking into consideration unbalanced number of observations. Abbreviations: ADAS, Alzheimer’s Disease Assessment Scale-Cognitive subscale; BPMSE, Baylor Profound Mental State Examination; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PI, Persistency Index (years drug use/years disease); PSMS, Physical Self-Maintenance Scale. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013 9, 338-345DOI: (10.1016/j.jalz.2012.01.002) Copyright © 2013 The Alzheimer's Association Terms and Conditions